Stock Price Forecast

Aug. 12, 2022


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Pluri Inc chart...

About the Company

Pluristem Therapeutics Inc. is a leading regenerative medicine company developing novel placenta-based cell therapy product candidates. The Company has reported robust clinical trial data in multiple indications for its patented PLX cell product candidates and is currently conducting late-stage clinical trials in several indications. PLX cell product candidates are believed to release a range of therapeutic proteins in response to inflammation, muscle trauma, hematological disorders and radiation damage. The cells are grown using the Company's proprietary three-dimensional expansion technology and can be administered to patients off- the-shelf, without tissue matching. Pluristem has a strong intellectual property position; a

CEO

Yaky Yanay

Exchange

NASDAQ

Website

www.pluristem.com

$0M

Total Revenue

152

Employees

$34M

Market Capitalization

-0.85

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $PSTI News

Pluri™ Receives First-Ever Patent Approval for 3D Bioreactor Technology in Plant Cell Cultivation

7d ago, source:

With over 140 active and granted patents, Pluri's robust IP portfolio is a testament to its pioneering role in the agtech industry. This patent, secured from the Israel Patent Office, further enhances ...

Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board

12d ago, source: Business Insider

HAIFA, Israel, March 06, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotech company that transforms cells into solutions that promote global ...

Pluri Selected as CDMO by Remedy Cell for Cell-Derived Cell-Free Drug Manufacturing

4d ago, source: Stockhouse

PluriCDMO™ will support Remedy Cell in the manufacture of RC-0315 product candidate for the treatment of Idiopathic Pulmonary Fibrosis (IPF) HAIFA, Israel, March 14, 2024 (GLOBE NEWSWIRE) -- Pluri Inc ...

Pluri's Innovation Across Various Industries: CEO Updates on Recent Achievements & 2024 Goals

19d ago, source: Stockhouse

Leading biotechnology company Pluri Inc. (NASDAQ:PLUR) (TASE:PLUR) (“Pluri” or the “Company”) today issued the following update from CEO and President, Yaky ...

Pluri Inc. launches cell-based coffee and CDMO division

19d ago, source: Investing

HAIFA, Israel - Pluri Inc. (NASDAQ:PLUR) (TASE:PLUR), a biotechnology firm, recently announced the launch of two new business verticals, PluriAgtech and PluriCDMO, aimed at leveraging its cell ...

Pluri Inc. (Y55.SG)

27d ago, source: Yahoo Finance

Pluri ( NASDAQ:PLUR ) Second Quarter 2024 Results Key Financial Results Net loss: US$4.91m (loss narrowed by 40% from... Simply Wall St. Pluri Full Year 2023 Earnings: US$0.77 loss per share (vs ...

Pluri(TM) Receives First-Ever Patent Approval for 3D Bioreactor Technology in Plant Cell Cultivation

7d ago, source: Stockhouse

Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or "the Company") today announced an important expansion to its intellectual property portfolio with a new patent approval, that is designed to reshape ...

Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board

12d ago, source: Nasdaq

HAIFA, Israel, March 06, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotech company that transforms cells into solutions that ...

Pluri Inc.: Pluri Selected as CDMO by Remedy Cell for Cell-Derived Cell-Free Drug Manufacturing

4d ago, source:

Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or "the Company"), a leading biotechnology company that transforms cells into solutions, today announced ...

Pluri’s Innovation Across Various Industries: CEO Updates on Recent Achievements & 2024 Goals

20d ago, source: Yahoo Finance

HAIFA, Israel, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Leading biotechnology company Pluri Inc. (NASDAQ:PLUR) (TASE:PLUR) (“Pluri” or the “Company”) today issued the following update from CEO ...

Pluri Inc. launches cell-based coffee and CDMO division

19d ago, source: Investing

HAIFA, Israel - Pluri Inc. (NASDAQ:PLUR) (TASE:PLUR), a biotechnology firm, recently announced the launch of two new business verticals, PluriAgtech and PluriCDMO, aimed at leveraging its cell-based ...

Pluri™ Receives First-Ever Patent Approval for 3D Bioreactor Technology in Plant Cell Cultivation

7d ago, source: Morningstar

HAIFA, Israel, March 11, 2024 (GLOBE NEWSWIRE) -- In a strategic move that underscores its innovative edge in the agtech sector, Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or "the Company ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...